{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T19:25:06Z","timestamp":1790623506320,"version":"4.1.0"},"reference-count":10,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofcardiologycases.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cardiology Cases"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.jccase.2021.09.001","type":"journal-article","created":{"date-parts":[[2021,9,19]],"date-time":"2021-09-19T23:59:34Z","timestamp":1632095974000},"page":"177-181","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Long-term effect of tocilizumab on left ventricular hypertrophy and systolic dysfunction in AA amyloidosis with rheumatoid arthritis"],"prefix":"10.1016","volume":"25","author":[{"given":"Satoshi","family":"Yamashita","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masao","family":"Saotome","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1865-1621","authenticated-orcid":false,"given":"Takeji","family":"Saitoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriyoshi","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Maekawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jccase.2021.09.001_bib0001","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1056\/NEJMoa065644","article-title":"Eprodisate for the treatment of renal disease in AA amyloidosis","volume":"356","author":"Dember","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jccase.2021.09.001_bib0002","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1056\/NEJMoa070265","article-title":"Natural history and outcome in systemic AA amyloidosis","volume":"356","author":"Lachmann","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jccase.2021.09.001_bib0003","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.2169\/internalmedicine.1099-18","article-title":"First nationwide survey of 199 patients with amyloid A amyloidosis in Japan","volume":"57","author":"Okuda","year":"2018","journal-title":"Intern Med"},{"key":"10.1016\/j.jccase.2021.09.001_bib0004","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/1529-0131(200101)44:1<66::AID-ANR10>3.0.CO;2-H","article-title":"The clinical significance of amyloid fat deposits in rheumatoid arthritis: a systematic long-term followup study using abdominal fat aspiration","volume":"44","author":"G\u00f3mez-Casanovas","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jccase.2021.09.001_bib0005","first-page":"948","article-title":"Prevalence of secondary amyloidosis in Asian North Indian patients with rheumatoid arthritis","volume":"30","author":"Wakhlu","year":"2003","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jccase.2021.09.001_bib0006","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1080\/14397595.2018.1515145","article-title":"AA amyloidosis - Benefits and prospects of IL-6 inhibitors","volume":"29","author":"Okuda","year":"2019","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.jccase.2021.09.001_bib0007","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3109\/14397595.2013.854048","article-title":"Comparison of the clinical utility of tocilizumab and anti-TNF therapy in AA amyloidosis complicating rheumatic diseases","volume":"24","author":"Okuda","year":"2014","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.jccase.2021.09.001_bib0008","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1248\/bpb.30.2001","article-title":"Recent advances in immunopathophysiology of interleukin-6: an innovative therapeutic drug, tocilizumab (recombinant humanized anti-human interleukin-6 receptor antibody), unveils the mysterious etiology of immune-mediated inflammatory diseases","volume":"30","author":"Ohsugi","year":"2007","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.jccase.2021.09.001_bib0009","doi-asserted-by":"crossref","first-page":"84","DOI":"10.3109\/13506129.2014.1002031","article-title":"AA amyloidosis treated with tocilizumab: case series and updated literature review","volume":"22","author":"Courties","year":"2015","journal-title":"Amyloid"},{"key":"10.1016\/j.jccase.2021.09.001_bib0010","doi-asserted-by":"crossref","first-page":"3186","DOI":"10.1007\/s00259-020-04861-4","article-title":"18 F-florbetaben positron emission tomography detects cardiac involvement in systemic AA amyloidosis","volume":"47","author":"Papathanasiou","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["Journal of Cardiology Cases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878540921001468?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878540921001468?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T06:12:07Z","timestamp":1761804727000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878540921001468"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":10,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["S1878540921001468"],"URL":"https:\/\/doi.org\/10.1016\/j.jccase.2021.09.001","relation":{},"ISSN":["1878-5409"],"issn-type":[{"value":"1878-5409","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term effect of tocilizumab on left ventricular hypertrophy and systolic dysfunction in AA amyloidosis with rheumatoid arthritis","name":"articletitle","label":"Article Title"},{"value":"Journal of Cardiology Cases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jccase.2021.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Japanese College of Cardiology. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}